<DOC>
	<DOC>NCT01056289</DOC>
	<brief_summary>Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release Formulation (DVS SR)</brief_summary>
	<brief_title>Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Primary Diagnosis of Major Depressive Disorder Hamilton Psychiatric Rating Scale for Depression17Item score of greater than or equal to 14 at baseline Current psychoactive substance abuse or dependence, manic episode, or a lifetime diagnosis of bipolar or psychotic disorder Potentially violent to others or is at significant risk for suicide History or current evidence of gastrointestinal disease or history of surgery known to interfere with absorption or excretion Known presence of raised intraocular pressure or history of narrow angle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>